Belgium
Every company in the roster headquartered in Belgium.
Every company in the roster headquartered in Belgium.
7 of 7 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Lakefront Biotherapeutics NVLKFT · Nasdaq | 1 asset: 1 Ph 3 | Gamgertamig (CM336)Phase 3 · Multiple Myeloma | Dec 2026Gamgertamig (CM336) · Phase 1/2 | $2.2B | $3.4BMar 2026 | — | $364M |
Agomab Therapeutics NVAGMB · Nasdaq | 1 asset: 1 Ph 2 | ontunisertibPhase 2 · Fibrostenosing Crohn's Disease | None on record | — | — | — | — |
UCBUCBJY · OTC | 16 assets: 10 approved, 1 Ph 3, 3 Ph 2, 2 Ph 1 | Staccato AlprazolamPhase 3 · EpilepsyReliable signal | 21 Dec 2026bimekizumab · Phase 3 | —no price since 18 Aug 2026 | — | — | ~$1.9B |
DeuterOncologyPrivate | 1 asset: 1 Ph 1 | DO-2Phase 1 · Non-Small Cell Lung Cancer | Sep 2027DO-2 · Phase 1 | — | — | — | — |
Flamingo TherapeuticsPrivate | 1 asset: 1 Ph 2 | DanvatirsenPhase 2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Inhatarget TherapeuticsPrivate | 1 asset: 1 Ph 2 | CIS-DPIPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Laboratoires SMB S.A.Private | 1 asset: 1 Ph 3 | PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.